San Diego, CA -- (SBWIRE) -- 05/23/2016 -- Berkeley, CA based clinical-stage immunotherapy company Aduro BioTech Inc is under investigation over potential securities laws violations. The investigation was announced on behalf of investors inNASDAQ:ADRO shares in connection certain financial statements made by Aduro BioTech Inc.

Investors who purchased shares of Aduro BioTech Inc (NASDAQ:ADRO), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call 858-779-1554.

The investigation by a law firm focuses on whether a series of statements by Aduro BioTech Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On May 16, 2016, Aduro BioTech Inc (NASDAQ:ADRO) announced that the Phase 2b ECLIPSE trial did not meet the primary endpoint of an improvement in overall survival for patients with pancreatic cancer who had failed at least two prior therapies in the metastatic setting.

Shares of Aduro BioTech Inc (NASDAQ:ADRO) declined to as low as $7.26 per share on May 16, 2016.

On May 19, 2016, NASDAQ:ADRO shares closed at $9.83 per share.

Those who purchased shares of Aduro BioTech Inc have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com